Compare Moderna, Inc. (MRNA) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Boston Beer Company Inc — how do they compare? Moderna, Inc. trades at $136.25 (market cap $54.14B), while Boston Beer Company Inc trades at $163.9 (market cap $1.67B). The key difference: Moderna, Inc. is far larger — about 32.4× Boston Beer Company Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals.
| MRNA | SAM | |
|---|---|---|
Market Cap | $54.14B | $1.67B |
Sector | Health | Consumer Staples |
52-Week High | $174.38 | $260.05 |
52-Week Low | $22.36 | $161.08 |
Enterprise Value | $50.29B | $1.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
SAM trades at $162.06, down 3.98% in the last session, with a bearish technical signal and key support at $158. The stock shows mixed fundamentals: revenue is stable near $2.0B, but net income turned negative in 2026 forecasts. Recent news includes a CFO transition and marketing leadership appointment, while earnings misses in Q1 and Q2 2026 highlight operational challenges.
The outlook is cautious; analyst consensus is a Hold with a $207.33 price target, but declining volumes and negative profit margins pose risks. Upside depends on execution of new brand initiatives and cost management, while competitive pressures and weak alcohol consumption trends remain headwinds for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
